Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” study

BACKGROUND AND AIM: Bulevirtide (BLV) blocks the uptake of the hepatitis D virus (HDV) into hepatocytes via the sodium/bile acid cotransporter NTCP. BLV was conditionally approved by the EMA but real‐life data on BLV efficacy are limited. METHODS: Patients were treated with BLV monotherapy. Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Jachs, Mathias, Schwarz, Caroline, Panzer, Marlene, Binter, Teresa, Aberle, Stephan W., Hartl, Lukas, Dax, Kristina, Aigner, Elmar, Stättermayer, Albert F., Munda, Petra, Graziadei, Ivo, Holzmann, Heidemarie, Trauner, Michael, Zoller, Heinz, Gschwantler, Michael, Mandorfer, Mattias, Reiberger, Thomas, Ferenci, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Bulevirtide in Chronic Hepatitis D Infection
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321570/
https://www.ncbi.nlm.nih.gov/pubmed/35514008
http://dx.doi.org/10.1111/apt.16945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321570/
https://www.ncbi.nlm.nih.gov/pubmed/35514008
http://dx.doi.org/10.1111/apt.16945

Ejemplares similares